Beijing Rejing Biotechnology Co., Ltd., established in June 2005, is a bio-high-tech enterprise with the mission of "developing biotechnology and benefiting human health".

The company continues to explore independent innovation diagnostic technology platforms, actively develop and expand liquid biopsy cancer early screening technology, and establish a multiomic diagnostic technology platform including protein markers, sugar chain exosomes, and DNA methylation; at the same time, it established the Future Technology Research Institute , explore cutting-edge technologies, actively deploy biopharmaceutical fields such as antibody drugs, live bacteria drugs, exosome drugs, and create a full-industry chain development strategy from diagnosis to treatment.

In the field of clinical diagnosis, the company has a number of cutting-edge innovative technologies and innovative products; after years of development, the company has built a bioactive raw material research and development platform, sugar capture technology platform, magnetic microparticle chemiluminescence technology platform, and upper forwarding technology platform in the field of clinical diagnosis. , colloidal gold immunochromatography technology platform, enzyme-linked immunology technology platform, molecular diagnostic technology platform, instrument R&D technology platform, etc.; establish a high-precision forwarding POCT (UPT series) platform to small and medium-sized The strategic layout of fully automatic single-person chemiluminescence platform (MQ60 instrument series), and then to the large high-throughput fully automatic chemiluminescence platform (C900, C2000, C3000), has realized the immune diagnosis from the primary medical market to the high-end medical market. Corporate strategy with full-scenario application as the goal.

公司检测菜单已涵盖炎症感染、心脑血管、骨代谢、甲功激素、糖尿病、高血压、肝炎肝癌、其他肿瘤等多种疾病的检测；并已实现单人份检测在国内基层医疗市场大范围Promote and apply it and the application of "triple test products for early diagnosis of liver cancer (AFP, AFP-L3%, DCP)" in most large benchmark tertiary hospitals. As one of the companies that obtained market access to the new crown antigen self-test products in Germany in 2021, the company has always practiced the core value of "quality determines the life and death of the company" and continued to provide excellent product supply to the global market; the new crown self-test reagent has been obtained one after another. EU CE, Germany BfArM, France ANSM, UK MHRA, Thailand TFDA, Singapore Health Sciences Bureau HSA, Brazil Health Bureau ANVISA and other major global registrations/registrations, exported to Germany, France, Italy, Austria, Hong Kong, Singapore, Vietnam, Thailand, Brazil, Peru and other nearly 40 countries and regions around the world are widely recognized and have become the mainstream products in the European home self-test market.

The company continues to expand its business and set up subsidiaries or offices in key markets such as Europe, India, and the Americas. The company was listed on the Science and Technology Innovation Board in 2019.

The company has always focused on technological innovation, continuously explored new diagnostic technologies and discovered new diagnostic markers; at the same time, it has continuously explored new business areas and accelerated its in-depth layout in the field of biopharmaceuticals.